These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 37324014)

  • 1. Afatinib combined with anti-PD1 enhances immunotherapy of hepatocellular carcinoma
    Yu C; Zhang X; Wang M; Xu G; Zhao S; Feng Y; Pan C; Yang W; Zhou J; Shang L; Ma Y
    Front Oncol; 2023; 13():1198118. PubMed ID: 37324014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meloxicam Inhibits Hepatocellular Carcinoma Progression and Enhances the Sensitivity of Immunotherapy via the MicroRNA-200/PD-L1 Pathway.
    Guangshun S; Guoqiang S; Xin C; Xiangyi K; Wubin Z; Zhitao L; Zhiying Z; Hongyong C; Chengyu L; Yongxiang X; Weiwei T
    J Oncol; 2022; 2022():4598573. PubMed ID: 35237322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macrophage GSK3β-deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy.
    Sun G; Liu H; Zhao J; Zhang J; Huang T; Sun G; Zhao S; Zhang Z; Cao H; Rong D; Kong X; Ji Q; Liu L; Wang X; Tang W; Xia Y
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HSF1 is involved in immunotherapeutic response through regulating APOJ/STAT3-mediated PD-L1 expression in hepatocellular carcinoma.
    Cheng H; Wang S; Huang A; Ma J; Gao D; Li M; Chen H; Guo K
    Cancer Biol Ther; 2023 Dec; 24(1):1-9. PubMed ID: 36482717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of PARP Potentiates Immune Checkpoint Therapy through miR-513/PD-L1 Pathway in Hepatocellular Carcinoma.
    Sun G; Miao G; Li Z; Zheng W; Zhou C; Sun G; Cao H; Li Z; Tang W
    J Oncol; 2022; 2022():6988923. PubMed ID: 35466317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 7. The hypoxia-inducible factor 1 inhibitor LW6 mediates the HIF-1α/PD-L1 axis and suppresses tumor growth of hepatocellular carcinoma in vitro and in vivo.
    Xu H; Chen Y; Li Z; Zhang H; Liu J; Han J
    Eur J Pharmacol; 2022 Sep; 930():175154. PubMed ID: 35868447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thymosin α1 suppresses migration and invasion of PD-L1 high-expressing non-small-cell lung cancer cells via inhibition of STAT3-MMP2 signaling.
    Bo C; Wu Q; Zhao H; Li X; Zhou Q
    Onco Targets Ther; 2018; 11():7255-7270. PubMed ID: 30425517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model.
    Kim KJ; Kim JH; Lee SJ; Lee EJ; Shin EC; Seong J
    Oncotarget; 2017 Jun; 8(25):41242-41255. PubMed ID: 28465485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. lncRNA MIAT targets miR-411-5p/STAT3/PD-L1 axis mediating hepatocellular carcinoma immune response.
    Zhang X; Pan B; Qiu J; Ke X; Shen S; Wang X; Tang N
    Int J Exp Pathol; 2022 Jun; 103(3):102-111. PubMed ID: 35429078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Over-Expression of GUSB Leads to Primary Resistance of Anti-PD1 Therapy in Hepatocellular Carcinoma.
    Kong X; Zheng Z; Song G; Zhang Z; Liu H; Kang J; Sun G; Sun G; Huang T; Li X; Rong D; Wang K; Tang W; Xia Y
    Front Immunol; 2022; 13():876048. PubMed ID: 35812439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aucubin enhances the antitumor activity of cisplatin through the inhibition of PD-L1 expression in hepatocellular carcinoma.
    Gao ZX; Zhang ZS; Qin J; Zhang MZ; Cao JL; Li YY; Wang MQ; Hou LL; Fang D; Xie SQ
    Phytomedicine; 2023 Apr; 112():154715. PubMed ID: 36821999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Midazolam exhibits antitumour and enhances the efficiency of Anti-PD-1 immunotherapy in hepatocellular carcinoma.
    Kang J; Zheng Z; Li X; Huang T; Rong D; Liu X; Qin M; Wang Y; Kong X; Song J; Lv C; Pan X
    Cancer Cell Int; 2022 Oct; 22(1):312. PubMed ID: 36224624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a PD-L1-Expressing Orthotopic Liver Cancer Model: Implications for Immunotherapy for Hepatocellular Carcinoma.
    Ou DL; Lin YY; Hsu CL; Lin YY; Chen CW; Yu JS; Miaw SC; Hsu PN; Cheng AL; Hsu C
    Liver Cancer; 2019 May; 8(3):155-171. PubMed ID: 31192153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Afatinib, an EGFR inhibitor, decreases EMT and tumorigenesis of Huh‑7 cells by regulating the ERK‑VEGF/MMP9 signaling pathway.
    Chen Y; Chen X; Ding X; Wang Y
    Mol Med Rep; 2019 Oct; 20(4):3317-3325. PubMed ID: 31432165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-derived PD1 and PD-L1 could promote hepatocellular carcinoma growth through autophagy induction in vitro.
    Chen Z; Liu S; Xie P; Zhang B; Yu M; Yan J; Jin L; Zhang W; Zhou B; Li X; Xiao Y; Xu Y; Ye Q; Li H; Guo L
    Biochem Biophys Res Commun; 2022 May; 605():82-89. PubMed ID: 35316767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
    Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib suppresses radioresistance and synergizes radiotherapy-mediated CD8
    Cheng CC; Ho AS; Peng CL; Chang J; Sie ZL; Wang CL; Chen YL; Chen CY
    Int Immunopharmacol; 2022 Nov; 112():109110. PubMed ID: 36037651
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    He L; Xu K; Niu L; Lin L
    Pharm Biol; 2022 Dec; 60(1):1710-1720. PubMed ID: 36086826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.